U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07129642) titled 'Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease' on Aug. 06.
Brief Summary: Graves' disease is an autoimmune disease. The TSH receptor antibody(TRab) produced by B cells drives the production of thyroid hormone, which causes systemic disorders and thyroid eye disease. The purpose of this study is to investigate the efficacy and safety of allogeneic anti-CD19 CAR-T for refractory Graves' disease.
The participants with refractory Graves' disease will receive a single dose of allogeneic anti-CD19 CAR-T and be regularly seen for the change of serum TRab, FT3, FT4 and clinical presentations, as well as any adverse events.
Stu...